GlassScriptPhysician profile
Drew Raymond Chronister
NPI 1811188543
$1,761.32
in general payments reported to CMS, 2019-2025
22 companies · $524 in 2025
The $524 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $78.97 · 2021: $220 · 2022: $152 · 2023: $147 · 2024: $436 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $652.43 | 2019-2025 | Clareon, Argos, Unity |
| Johnson & Johnson Surgical Vision, INC. | $187.61 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $141.43 | 2022-2025 | Vyzulta, Biotrue One Day, Infuse |
| Sun Pharmaceutical Industries INC. | $116.02 | 2019-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $75.97 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $67.99 | 2023-2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Dompe US, INC. | $60.58 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $51.45 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $48.81 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $43.09 | 2021-2022 | |
| Allergan, INC. | $41.31 | 2020-2021 | |
| Ocular Therapeutix, INC. | $34.67 | 2019-2023 | Dextenza |
| Akorn Operating Company LLC | $33.29 | 2021 | |
| Harrow Eye, LLC | $32.09 | 2025 | Iheezo |
| Amgen INC. | $31.86 | 2024 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.18 | 2019 | |
| Astellas Pharma US INC | $24.96 | 2025 | Izervay |
| Abbvie INC. | $23.80 | 2025 | |
| Omeros Corporation | $21.41 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Abb Con-Cise Optical Group LLC | $13.62 | 2024 | Contact Lens, Spectacle Lenses |
| Thea Pharma INC. | $13.35 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Chronister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.